Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Rheumatology Reviews
  4. Fast Track Articles
  5. Fast Track Article
image of Upadacitinib and Cardiovascular Adverse Events in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Abstract

Background

Upadacitinib, a Janus kinase (JAK) inhibitor used in rheumatoid arthritis treatment, has prompted safety concerns due to potential cardiovascular adverse events. However, current evidence does not provide a definitive conclusion.

Methods

We conducted a comprehensive systematic review of the literature up until March 15, 2024, utilizing databases like PubMed/Medline, Embase, and Cochrane CENTRAL. A meta-analysis approach was used to derive pooled odds ratios (OR) along with their 95% confidence intervals (CI) to assess the cardiovascular risk associated with upadacitinib. Publication bias was evaluated using Begg's and Egger's tests.

Results

Our meta-analysis included six studies with a total of 4,202 participants. For the 15 mg dosage of Upadacitinib, the pooled OR was 1.20 (95% CI: 0.3-4.3), indicating a nominal, non-significant increase in the risk of cardiovascular adverse events. Analysis of the 30 mg dosage presented a pooled OR of 2.37 (95% CI: 0.6-9.1), pointing to a higher, yet statistically insignificant, potential risk. The absence of publication bias was confirmed through Begg's and Egger’s tests.

Conclusion

The analysis suggests a potential heightened cardiovascular risk associated with Upadacitinib, more so with the 30 mg dosage. Nevertheless, the lack of statistical significance and the wide confidence intervals necessitate a prudent approach to these findings. Tailored treatment strategies, rigorous monitoring, and further empirical studies are crucial for refining the safety profile of upadacitinib and ensuring optimal patient outcomes.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crr/10.2174/0115733971342481241101061013
2024-11-07
2025-01-24

  • From This Site

    /content/journals/crr/10.2174/0115733971342481241101061013
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Radu A.F. Bungau S.G. Management of rheumatoid arthritis: An overview. Cells 2021 10 11 2857 10.3390/cells10112857
    [Google Scholar]
  2. Scherer H.U. Häupl T. Burmester G.R. The etiology of rheumatoid arthritis. J. Autoimmun. 2020 110 102400 10.1016/j.jaut.2019.102400
    [Google Scholar]
  3. Weyand C.M. Goronzy J.J. The immunology of rheumatoid arthritis. Nat. Immunol. 2021 22 1 10 18 10.1038/s41590‑020‑00816‑x
    [Google Scholar]
  4. Almutairi K. Nossent J. Preen D. Keen H. Inderjeeth C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol. Int. 2021 41 5 863 877 10.1007/s00296‑020‑04731‑0
    [Google Scholar]
  5. Safiri S. Kolahi A.A. Hoy D. Smith E. Bettampadi D. Mansournia M.A. Hashiani A.A. Asgarabad A.A. Lakeh M.M. Qorbani M. Collins G. Woolf A.D. March L. Cross M. Global, regional and national burden of rheumatoid arthritis 1990–2017: A systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 2019 78 11 1463 1471 10.1136/annrheumdis‑2019‑215920
    [Google Scholar]
  6. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr. Opin. Chem. Biol. 2016 32 29 33 10.1016/j.cbpa.2016.03.006
    [Google Scholar]
  7. O’Shea J.J. Kontzias A. Yamaoka K. Tanaka Y. Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 2013 72 2 ii111 ii115 10.1136/annrheumdis‑2012‑202576
    [Google Scholar]
  8. Langbour C. Rene J. Goupille P. Alegria C.G. Efficacy of Janus kinase inhibitors in rheumatoid arthritis. Inflamm. Res. 2023 72 5 1121 1132 10.1007/s00011‑023‑01717‑z
    [Google Scholar]
  9. Lee S.W. Incidence if autoimmune inflammatory rheumatic diseases after COVID-19 in South Korea: A nationwide cohort study based on health insurance data Wiley Online Library 2024 27 6 e15219
    [Google Scholar]
  10. Park J. Lee M. Lee H. Kim H.J. Kwon R. Yang H. Lee S.W. Kim S. Rahmati M. Koyanagi A. Smith L. Kim M.S. Jacob L. Sánchez L.G.F. Elena D. Shin J.I. Rhee S.Y. Yoo M.C. Yon D.K. National trends in rheumatoid arthritis and osteoarthritis prevalence in South Korea, 1998–2021. Sci. Rep. 2023 13 1 19528 10.1038/s41598‑023‑46279‑6
    [Google Scholar]
  11. Wu D. Jin Y. Xing Y. Abate M.D. Abbasian M. Kangevari A.M. Kangevari A.Z. Allah A.F. Abdelmasseh M. Abdollahifar M-A. Abdulah D.M. Abedi A. Abedi V. Abidi H. Aboagye R.G. Abolhassani H. Abuabara K. Abyadeh M. Addo I.Y. Adeniji K.N. Adepoju A.V. Adesina M.A. Adnani S.Q.E. Afarideh M. Aghamiri S. Agodi A. Agrawal A. Arriagada A.C.E. Ahmad A. Ahmad D. Ahmad S. Ahmad S. Ahmadi A. Ahmed A. Ahmed A. Aithala J.P. Ajadi A.A. Ajami M. Khiavi A.M. Alahdab F. AlBataineh M.T. Alemi S. Gheethi S.A.A.A. Ali L. Alif S.M. Almazan J.U. Almustanyir S. Alqahtani J.S. Alqasmi I. Altaf K.I.U. Guzman A.N. Zakzuk A.N.J. Worafi A.Y.M. Aly H. Amani R. Amu H. Amusa G.A. Andrei C.L. Ansar A. Ansariniya H. Anyasodor A.E. Arabloo J. Arefnezhad R. Arulappan J. Jafarabadi A.M. Ashraf T. Atata J.A. Athari S.S. Atlaw D. Atout W.M.M. Aujayeb A. Awan A.T. Ayatollahi H. Azadnajafabad S. Azzam A.Y. Badawi A. Badiye A.D. Bagherieh S. Baig A.A. Bantie B.B. Barchitta M. Bardhan M. Collo B.S.L. Adesi B.F. Batra K. Bayileyegn N.S. Behnoush A.H. Belgaumi U.I. Bemanalizadeh M. Bensenor I.M. Beyene K.A. Bhagavathula A.S. Bhardwaj P. Bhaskar S. Bhat A.N. Bitaraf S. Bitra V.R. Boloor A. Bora K. Botelho J.S. Buchbinder R. Calina D. Cámera L.A. Carvalho A.F. Chan K.J.S. Chattu V.K. Abebe E.C. Chichagi F. Choi S. Chou T-C. Chu D-T. Coberly K. Costa V.M. Couto R.A.S. Martins C.N. Dadras O. Dai X. Damiani G. Dascalu A.M. Dashti M. Debela S.A. Dellavalle R.P. Demetriades A.K. Demlash A.A. Deng X. Desai H.D. Desai R. Dewan R.S.M. Dey S. Dharmaratne S.D. Diaz D. Dibas M. Oliveira D.R.J. Diress M. Do T.C. Doan D.K. Dodangeh M. Dodangeh M. Dongarwar D. Dube J. Dziedzic A.M. Dra E.A. Edinur H.A. Eissazade N. Ekholuenetale M. Ekundayo T.C. Elemam N.M. Elhadi M. Elmehrath A.O. Elmeligy A.O.A. Emamverdi M. Emeto T.I. Esayas H.L. Eshetu H.B. Etaee F. Fagbamigbe A.F. Faghani S. Fakhradiyev I.R. Fatehizadeh A. Fathi M. Feizkhah A. Fekadu G. Fereidouni M. Fereshtehnejad S-M. Fernandes J.C. Ferrara P. Fetensa G. Filip I. Fischer F. Foroutan B. Foroutan M. Fukumoto T. Ganesan B. Gemeda B.B.N. Ghamari S-H. Ghasemi M.R. Gholamalizadeh M. Gill T.K. Gillum R.F. Goldust M. Golechha M. Goleij P. Golinelli D. Goudarzi H. Guan S-Y. Guo Y. Gupta B. Gupta V.B. Gupta V.K. Haddadi R. Hadi N.R. Halwani R. Haque S. Hasan I. Hashempour R. Hassan A. Hassan T.S. Hassanzadeh S. Hassen M.B. Haubold J. Hayat K. Heidari G. Heidari M. Soureshjani H.R. Herteliu C. Hessami K. Hezam K. Hiraike Y. Holla R. Hosseini M-S. Huynh H-H. Hwang B-F. Ibitoye S.E. Ilic I.M. Ilic M.D. Iranmehr A. Iravanpour F. Ismail N.E. Iwagami M. Iwu C.C.D. Jacob L. Jafarinia M. Jafarzadeh A. Jahankhani K. Jahrami H. Jakovljevic M. Jamshidi E. Jani C.T. Janodia M.D. Jayapal S.K. Jayaram S. Jeganathan J. Jonas J.B. Joseph A. Joseph N. Joshua C.E. Vaishali K. Kaambwa B. Kabir A. Kabir Z. Kadashetti V. Kaliyadan F. Kalroozi F. Kamal V.K. Kandel A. Kandel H. Kanungo S. Karami J. Karaye I.M. Karimi H. Kasraei H. Kazemian S. Kebede S.A. Arani K.L. Keykhaei M. Khader Y.S. Khajuria H. Khamesipour F. Khan E.A. Khan I.A. Khan M. Khan M.J. Khan M.A.B. Khan M.A. Khatatbeh H. Khatatbeh M.M. Khateri S. Kashani K.H.R. Kim M.S. Kisa A. Kisa S. Koh H.Y. Kolkhir P. Korzh O. Kotnis A.L. Koul P.A. Koyanagi A. Krishan K. Kuddus M. Kulkarni V.V. Kumar N. Kundu S. Kurmi O.P. Vecchia L.C. Lahariya C. Laksono T. Lám J. Latief K. Lauriola P. Lawal B.K. Le T.T.T. Bich Le T.T. Lee M. Lee S.W. Lee W-C. Lee Y.H. Lenzi J. Levi M. Li W. Ligade V.S. Lim S.S. Liu G. Liu X. Llanaj E. Lo C-H. Machado V.S. Maghazachi A.A. Mahmoud M.A. Mai T.A. Majeed A. Sanaye P.M. Makram O.M. Rad E.M. Malhotra K. Malik A.A. Malik I. Mallhi T.H. Malta D.C. Mansournia M.A. Mantovani L.G. Martorell M. Masoudi S. Masoumi S.Z. Mathangasinghe Y. Mathews E. Mathioudakis A.G. Maugeri A. Mayeli M. Medina C.J.R. Meles G.G. Mendes J.J. Menezes R.G. Mestrovic T. Michalek I.M. Sá M.G.N.D.A.C. Mihretie E.T. Nhat Minh L.H. Mirfakhraie R. Mirrakhimov E.M. Misganaw A. Mohamadkhani A. Mohamed N.S. Mohammadi F. Mohammadi S. Mohammed S. Mohammed S. Mohan S. Mohseni A. Mokdad A.H. Momtazmanesh S. Monasta L. Moni M.A. Moniruzzaman M. Moradi Y. Morovatdar N. Mostafavi E. Mousavi P. Mukoro G.D. Mulita A. Mulu G.B. Zamora M.E. Musaigwa F. Mustafa G. Muthu S. Nainu F. Nangia V. Swamy S.N. Natto Z.S. Navaraj P. Nayak B.P. Panjaki N.A. Negash H. Nematollahi M.H. Nguyen D.H. Nguyen H.H.T. Nguyen H.Q. Nguyen P.T. Nguyen V.T. Niazi R.K. Nikolouzakis T.K. Nnyanzi L.A. Noreen M. Nzoputam C.I. Nzoputam O.J. Oancea B. Oh I-H. Aliabad O.H. Okonji O.C. Okwute P.G. Olagunju A.T. Olatubi M.I. Olufadewa I.I. Ordak M. Otstavnov N. Owolabi M.O. Mahesh P.A. Padubidri J.R. Pak A. Pakzad R. Palladino R. Pana A. Pantazopoulos I. Papadopoulou P. Pardhan S. Parthasarathi A. Pashaei A. Patel J. Pathan A.R. Patil S. Paudel U. Pawar S. Pedersini P. Pensato U. Pereira D.M. Pereira J. Pereira M.O. Pereira R.B. Peres M.F.P. Perianayagam A. Perna S. Petcu I-R. Pezeshki P.S. Pham H.T. Philip A.K. Piradov M.A. Podder I. Podder V. Poddighe D. Prates S.E.J. Qattea I. Radfar A. Raee P. Rafiei A. Raggi A. Rahim F. Rahimi M. Rahimifard M. Movaghar R.V. Rahman M.O. Rahman U.M.H. Rahman M. Rahman M.A. Rahmani A.M. Rahmani M. Rahmani S. Rahmanian V. Ramasubramani P. Rancic N. Rao I.R. Rashedi S. Rashid A.M. Ravikumar N. Rawaf S. Redwan M.E.M. Rezaei N. Rezaei N. Rezaei N. Rezaeian M. Ribeiro D. Rodrigues M. Rodriguez B.J.A. Roever L. Rodríguez R.E. Saad A.M.A. Saddik B. Sadeghian S. Saeed U. Safary A. Safdarian M. Safi S.Z. Saghazadeh A. Sagoe D. Askari S.F.S. Askari S.N.S. Sahebkar A. Sahoo H. Sahraian M.A. Sajid M.R. Sakhamuri S. Sakshaug J.W. Saleh M.A. Salehi L. Salehi S. Farrokhi A.S. Samadzadeh S. Samargandy S. Samieefar N. Samy A.M. Sanadgol N. Sanjeev R.K. Sawhney M. Saya G.K. Schuermans A. Senthilkumaran S. Sepanlou S.G. Sethi Y. Shafie M. Shah H. Shahid I. Shahid S. Shaikh M.A. Sharfaei S. Sharma M. Shayan M. Shehata H.S. Sheikh A. Shetty J.K. Shin J.I. Shirkoohi R. Shitaye N.A. Shivakumar K.M. Shivarov V. Shobeiri P. Siabani S. Sibhat M.M. Siddig E.E. Simpson C.R. Sinaei E. Singh H. Singh I. Singh J.A. Singh P. Singh S. Siraj M.S. Sohag A.M.A. Solanki R. Solikhah S. Solomon Y. Zangbar S.M.S. Sun J. Szeto M.D. Seisdedos T.R. Tabatabaei S.M. Tabish M. Taheri E. Tahvildari A. Talaat I.M. Tamuzi L.J.J.L. Tan K-K. Tat N.Y. Oliaee R.T. Tavasol A. Temsah M-H. Thangaraju P. Tharwat S. Tibebu N.S. Ticoalu V.J.H. Tillawi T. Tiruye T.Y. Tiyuri A. Palone T.M.R. Tripathi M. Tsegay G.M. Tualeka A.R. Ty S.S. Ubah C.S. Ullah S. Ullah S. Umair M. Umakanthan S. Upadhyay E. Vahabi S.M. Vaithinathan A.G. Tahbaz S.V. Valizadeh R. Varthya S.B. Vasankari T.J. Venketasubramanian N. Verras G-I. Villafañe J.H. Vlassov V. Vo D.C. Waheed Y. Waris A. Welegebrial B.G. Westerman R. Wickramasinghe D.P. Wickramasinghe N.D. Willekens B. Woldegeorgis B.Z. Woldemariam M. Xiao H. Yada D.Y. Yahya G. Yang L. Yazdanpanah F. Yon D.K. Yonemoto N. You Y. Zahir M. Zaidi S.S. Zangiabadian M. Zare I. Zeineddine M.A. Zemedikun D.T. Zeru N.G. Zhang C. Zhao H. Zhong C. Zielińska M. Zoladl M. Zumla A. Guo C. Tam L. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: Findings from the global burden of disease study 2019. E. Clin. Med. 2023 64 102193 10.1016/j.eclinm.2023.102193
    [Google Scholar]
  12. Scott I.C. Hider S.L. Scott D.L. Thromboembolism with janus kinase (JAK) inhibitors for rheumatoid arthritis: How real is the risk? Drug Saf. 2018 41 7 645 653 10.1007/s40264‑018‑0651‑5
    [Google Scholar]
  13. Kotyla P.J. Islam M.A. Engelmann M. Clinical aspects of janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int. J. Mol. Sci. 2020 21 19 7390 10.3390/ijms21197390
    [Google Scholar]
  14. Misra D.P. Pande G. Agarwal V. Cardiovascular risks associated with Janus kinase inhibitors: Peering outside the black box. Clin. Rheumatol. 2023 42 2 621 632 10.1007/s10067‑022‑06415‑5
    [Google Scholar]
  15. Nash P. Lim I. Marabani M. A comparison of janus kinase inhibitor safety in rheumatoid arthritis. Int. J. Rheum. Dis. 2021 24 S1 3 14 10.1111/1756‑185X.14127
    [Google Scholar]
  16. Atzeni F. Carrio R.J. Popa C.D. Nurmohamed M.T. Szűcs G. Szekanecz Z. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nat. Rev. Rheumatol. 2021 17 5 270 290 10.1038/s41584‑021‑00593‑3
    [Google Scholar]
  17. Yang J.M. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: A world health organization pharmacovigilance study. Ophthalmology 2024 S0161-6420 24 00419 6 10.1016/j.ophtha.2024.07.008
    [Google Scholar]
  18. Crowson C.S. Rheumatoid arthritis and cardiovascular disease. American Hear. J. 2013 166 4 622 628 10.1016/j.ahj.2013.07.010
    [Google Scholar]
  19. Fleischmann R. Curtis J.R. Schoeman C.C. Mysler E. Yamaoka K. Richez C. Palac H. Dilley D. Liu J. Strengholt S. Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: Integrated post hoc analysis of the select phase III rheumatoid arthritis clinical programme. Ann. Rheum. Dis. 2023 82 9 1130 1141 10.1136/ard‑2023‑223916
    [Google Scholar]
  20. Fleischmann R. Mysler E. Bessette L. Peterfy C.G. Durez P. Tanaka Y. Swierkot J. Khan N. Bu X. Li Y. Song I-H. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: Results through 3 years from the select-compare study. RMD Open 2022 8 1 e002012 10.1136/rmdopen‑2021‑002012
    [Google Scholar]
  21. Cohen S.B. Vollenhoven V.R.F. Winthrop K.L. Zerbini C.A.F. Tanaka Y. Bessette L. Zhang Y. Khan N. Hendrickson B. Enejosa J.V. Burmester G.R. Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the select phase III clinical programme. Ann. Rheum. Dis. 2021 80 3 304 311 10.1136/annrheumdis‑2020‑218510
    [Google Scholar]
  22. Page M.J. McKenzie J.E. Bossuyt P.M. Boutron I. Hoffmann T.C. Mulrow C.D. Shamseer L. Tetzlaff J.M. Akl E.A. Brennan S.E. Chou R. Glanville J. Grimshaw J.M. Hróbjartsson A. Lalu M.M. Li T. Loder E.W. Wilson M.E. McDonald S. McGuinness L.A. Stewart L.A. Thomas J. Tricco A.C. Welch V.A. Whiting P. Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021 88 105906 10.1016/j.ijsu.2021.105906
    [Google Scholar]
  23. Anderson J. Caplan L. Yazdany J. Robbins M.L. Neogi T. Michaud K. Saag K.G. O’dell J.R. Kazi S. Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012 64 5 640 647 10.1002/acr.21649
    [Google Scholar]
  24. Burmester G.R. Kremer J.M. Bosch V.D.F. Kivitz A. Bessette L. Li Y. Zhou Y. Othman A.A. Pangan A.L. Camp H.S. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018 391 10139 2503 2512 10.1016/S0140‑6736(18)31115‑2
    [Google Scholar]
  25. Genovese M.C. Fleischmann R. Combe B. Hall S. Roth R.A. Zhang Y. Zhou Y. Mohamed M-E.F. Meerwein S. Pangan A.L. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial. Lancet 2018 391 10139 2513 2524 10.1016/S0140‑6736(18)31116‑4
    [Google Scholar]
  26. Fleischmann R. Pangan A.L. Song I-H. Mysler E. Bessette L. Peterfy C. Durez P. Ostor A.J. Li Y. Zhou Y. Othman A.A. Genovese M.C. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019 71 11 1788 1800 10.1002/art.41032
    [Google Scholar]
  27. Smolen J.S. Pangan A.L. Emery P. Rigby W. Tanaka Y. Vargas J.I. Zhang Y. Damjanov N. Friedman A. Othman A.A. Camp H.S. Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019 393 10188 2303 2311 10.1016/S0140‑6736(19)30419‑2
    [Google Scholar]
  28. Vollenhoven V.R. Takeuchi T. Pangan A.L. Friedman A. Mohamed M-E.F. Chen S. Rischmueller M. Blanco R. Xavier R.M. Strand V. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): A multicenter, multi-country, randomized, double-blind, active comparator–controlled trial. Arthritis Rheumatol. 2020 72 10 1607 1620 10.1002/art.41384
    [Google Scholar]
  29. Kameda H. Takeuchi T. Yamaoka K. Oribe M. Kawano M. Zhou Y. Othman A.A. Pangan A.L. Kitamura S. Meerwein S. Tanaka Y. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): A placebo-controlled phase IIb/III study. Rheumatology 2020 59 11 3303 3313 10.1093/rheumatology/keaa084
    [Google Scholar]
  30. VanMil V.D.H.A.H.M. Cessie L.S. Dongen V.H. Breedveld F.C. Toes R.E.M. Huizinga T.W.J. A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions. Arthritis Rheum. 2007 56 2 433 440 10.1002/art.22380
    [Google Scholar]
  31. Vollenhoven V.R. Treat-to-target in rheumatoid arthritis — Are we there yet? Nat. Rev. Rheumatol. 2019 15 3 180 186 10.1038/s41584‑019‑0170‑5
    [Google Scholar]
  32. Fraenkel L. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021 73 7 1108 1123 10.1002/art.41752
    [Google Scholar]
  33. Danese S. Vermeire S. Zhou W. Pangan A.L. Siffledeen J. Greenbloom S. Hébuterne X. D’Haens G. Nakase H. Panés J. Higgins P.D.R. Juillerat P. Lindsay J.O. Loftus E.V. Jr Sandborn W.J. Reinisch W. Chen M-H. Gonzalez S.Y. Huang B. Xie W. Liu J. Weinreich M.A. Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022 399 10341 2113 2128 10.1016/S0140‑6736(22)00581‑5
    [Google Scholar]
  34. Sandborn W.J. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020 158 8 2139 2149 10.1053/j.gastro.2020.02.030
    [Google Scholar]
  35. Bobadilla P.A.V. Stodtmann S. Eckert D. Zhou W. Liu W. Mohamed M-E.F. Upadacitinib population pharmacokinetics and exposure-response relationships in ulcerative colitis patients. Clin. Pharmacokinet. 2023 62 1 101 112 10.1007/s40262‑022‑01191‑6
    [Google Scholar]
  36. Dougados M. Soubrier M. Antunez A. Balint P. Balsa A. Buch M.H. Casado G. Detert J. Zorkany E.B. Emery P. Hassouni H.N. Harigai M. Luo S-F. Kurucz R. Maciel G. Mola E.M. Montecucco C.M. McInnes I. Radner H. Smolen J.S. Song Y-W. Vonkeman H.E. Winthrop K. Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014 73 1 62 68 10.1136/annrheumdis‑2013‑204223
    [Google Scholar]
  37. Riel V.P. Alten R. Combe B. Abdulganieva D. Bousquet P. Courtenay M. Curiale C. Centeno G.A. Haugeberg G. Leeb B. Puolakka K. Ravelli A. Rintelen B. Puttini S.P. Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools. RMD Open 2016 2 2 e000302 10.1136/rmdopen‑2016‑000302
    [Google Scholar]
  38. Khusainova M.A. Cardiac arrhythmias in patients with rheumatoid arthritis. Sci. Educ. 2023 4 2 130 137
    [Google Scholar]
  39. Dhillon N. Liang K. Prevention of stroke in rheumatoid arthritis. Curr. Treat. Options Neurol. 2015 17 7 31 10.1007/s11940‑015‑0356‑3
    [Google Scholar]
/content/journals/crr/10.2174/0115733971342481241101061013
Loading
Upadacitinib and Cardiovascular Adverse Events in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0115733971342481241101061013
/content/journals/crr/10.2174/0115733971342481241101061013
/content/journals/crr/10.2174/0115733971342481241101061013
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: cardiovascular adverse events ; Upadacitinib ; Janus kinase inhibitor ; rheumatoid arthritis ; meta-analysis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test